睿知中国医院研究地图
候选清单

正在招募肺癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Multicenter, Single-Arm, Prospective Phase II Study of Neoadjuvant Cryo-Thermal Ablation Combined With Toripalimab and Chemotherapy for Resectable Stage IB-IIIB Non-Small Cell Lung Cancer

ClinicalTrials.gov 上登记的一项肺癌开放试验,由四川大学华西医院牵头,本站收录的另外 3 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 4

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方四川大学华西医院West China Hospital成都医院页面
  2. 研究中心川北医学院附属医院Affiliated Hospital of North Sichuan Medical College南充医院页面
  3. 研究中心西南医科大学附属医院Affiliated Hospital of Southwest Medical University泸州医院页面
  4. 研究中心四川省肿瘤医院Sichuan Cancer Hospital成都医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07855965,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 8

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(8 项)收起清单
  1. 18 岁 至 80 岁;性别:不限

    登记记录的入选字段

  2. Histologically or cytologically confirmed non-small cell lung cancer (NSCLC).

    入选标准第 2 条

    The primary lung lesion must be technically amenable to percutaneous biopsy and CT-guided Cryo-Thermal Ablation..

    入选标准第 6 条

  3. Clinical stage IB-IIIB according to the 9th edition IASLC/AJCC TNM classification.

    入选标准第 3 条

    For stage IB disease, only patients with a maximum tumor diameter of 4.0 cm (cT2aN0M0) are eligible.

    入选标准第 4 条

  4. Female participants of childbearing potential and male participants with partners of childbearing potential must agree to use effective contraception from enrollment until at least 180 days after the last dose of study systemic therapy.

    入选标准第 27 条

  5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

    入选标准第 10 条

  6. Hemoglobin ≥9.0 g/dL;

    入选标准第 17 条

    absolute neutrophil count ≥1.0 × 10⁹/L;

    入选标准第 18 条

    platelet count ≥90 × 10⁹/L;

    入选标准第 19 条

    total bilirubin ≤2.0 × upper limit of normal (ULN);

    入选标准第 20 条

    alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) ≤2.5 × ULN;

    入选标准第 21 条

    serum creatinine ≤2.0 mg/dL and creatinine clearance ≥60 mL/min;

    入选标准第 22 条

    international normalized ratio (INR) ≤1.5 and activated partial thromboplastin time (APTT) ≤1.5 × ULN, unless abnormalities are attributable to protocol-permitted anticoagulation.

    入选标准第 24 条

    EGFR sensitizing or protocol-defined activating alterations, including exon 19 deletion, L858R, G719X, S768I, L861Q, or exon 20 insertion;

    排除标准第 4 条

  7. Small-cell lung cancer (SCLC) or mixed histology containing a small-cell component.

    排除标准第 2 条

    Active tuberculosis or inadequately controlled tuberculosis treated within 1 year before enrollment.

    排除标准第 30 条

    Active hepatitis B infection with HBV DNA above the protocol-defined acceptable limit.

    排除标准第 32 条

    Active hepatitis C infection with detectable HCV RNA.

    排除标准第 33 条

    Another malignancy diagnosed within 2 years before enrollment, except malignancies with a negligible risk of metastasis or death that have been adequately treated, such as basal cell or squamous cell carcinoma of the skin or carcinoma in situ treated with curative intent.

    排除标准第 40 条

    Receipt of anti-cancer traditional Chinese patent medicines or systemic immunomodulatory agents, including thymosin, interferons, or interleukins, within 2 weeks before initiation of study treatment.

    排除标准第 43 条

  8. Female participants of childbearing potential must have a negative serum or urine human chorionic gonadotropin (HCG) pregnancy test within 7 days before initiation of study treatment.

    入选标准第 26 条

    Pregnancy, Lactation, and Transplantation

    排除标准第 45 条

    Pregnancy or breastfeeding.

    排除标准第 46 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07855965,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Diagnosis, Stage, and Resectability
  2. Histologically or cytologically confirmed non-small cell lung cancer (NSCLC).
  3. Clinical stage IB-IIIB according to the 9th edition IASLC/AJCC TNM classification.
  4. For stage IB disease, only patients with a maximum tumor diameter of 4.0 cm (cT2aN0M0) are eligible.
  5. The disease must be considered resectable by multidisciplinary team (MDT) assessment with curative-intent surgery planned after neoadjuvant treatment.
  6. The primary lung lesion must be technically amenable to percutaneous biopsy and CT-guided Cryo-Thermal Ablation..
  7. No prior systemic or local anti-tumor therapy for the current NSCLC.
  8. Age, Performance Status, and General Condition
  9. Age 18-80 years.
  10. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
  11. Estimated life expectancy >6 months.
  12. Able to understand and voluntarily sign the informed consent form and willing to comply with study treatment, specimen collection, and follow-up requirements.
  13. Tumor Tissue and Pulmonary Function
  14. Willing to provide tumor tissue and blood samples required by the study protocol.
  15. Adequate pulmonary function for the planned treatment and subsequent pulmonary resection, including: FEV1 ≥1.2 L or ≥50% of predicted value; and predicted postoperative FEV1≥30% of predicted value.
  16. Adequate Organ Function
  17. Hemoglobin ≥9.0 g/dL;
  18. absolute neutrophil count ≥1.0 × 10⁹/L;
  19. platelet count ≥90 × 10⁹/L;
  20. total bilirubin ≤2.0 × upper limit of normal (ULN);
  21. alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) ≤2.5 × ULN;
  22. serum creatinine ≤2.0 mg/dL and creatinine clearance ≥60 mL/min;
  23. adequate thyroid function. If thyroid-stimulating hormone (TSH) is outside the normal range, free T3 and free T4 must be within clinically acceptable limits; no clinically significant abnormality in cardiac enzyme testing;
  24. international normalized ratio (INR) ≤1.5 and activated partial thromboplastin time (APTT) ≤1.5 × ULN, unless abnormalities are attributable to protocol-permitted anticoagulation.
  25. Reproductive Requirements
  26. Female participants of childbearing potential must have a negative serum or urine human chorionic gonadotropin (HCG) pregnancy test within 7 days before initiation of study treatment.
  27. Female participants of childbearing potential and male participants with partners of childbearing potential must agree to use effective contraception from enrollment until at least 180 days after the last dose of study systemic therapy.

排除标准:Exclusion Criteria:

  1. Histological or Molecular Characteristics
  2. Small-cell lung cancer (SCLC) or mixed histology containing a small-cell component.
  3. Presence of protocol-defined actionable oncogenic alterations detected by tumor tissue and/or plasma-based molecular testing, including:
  4. EGFR sensitizing or protocol-defined activating alterations, including exon 19 deletion, L858R, G719X, S768I, L861Q, or exon 20 insertion;
  5. ALK rearrangement;
  6. ROS1 rearrangement;
  7. MET exon 14 skipping alteration or protocol-defined MET amplification;
  8. KRAS G12C;
  9. BRAF V600E;
  10. NTRK1/2/3 fusion;
  11. RET rearrangement; or HER2 alteration as defined in the study protocol.
  12. Contraindications to Percutaneous Biopsy or Cryo-Thermal Ablation
  13. Active clinically significant hemoptysis, defined as ≥1/2 teaspoon of fresh blood, within 2 weeks before the planned procedure.
  14. Clinically significant bleeding tendency or coagulation disorder that cannot be adequately corrected before biopsy or ablation.
  15. Therapeutic anticoagulant or vitamin K antagonist treatment that cannot be safely interrupted or managed during the periprocedural period according to the study protocol and institutional practice. Stable anticoagulation may be permitted when appropriate periprocedural interruption or management is considered safe by the investigator.
  16. Active infection involving the planned biopsy or ablation site or access pathway.
  17. Any anatomical or clinical condition considered by the investigator to make percutaneous biopsy or combined Cryo-Thermal Ablation unsafe.
  18. Clinically Significant Cardiovascular or Systemic Disease
  19. Uncontrolled hypertension.
  20. Unstable angina, myocardial infarction within 3 months before enrollment, New York Heart Association (NYHA) class II or higher heart failure considered clinically significant by the investigator, or severe/uncontrolled arrhythmia.
  21. Severe or uncontrolled hepatic, renal, metabolic, or other systemic disease that could interfere with study treatment or assessment.
  22. Immunotherapy-Related Contraindications
  23. Active or suspected autoimmune disease requiring systemic treatment, except for conditions permitted by the protocol, such as vitiligo, type 1 diabetes mellitus, or adequately controlled autoimmune hypothyroidism.
  24. History of autoimmune disease requiring systemic treatment with disease-modifying agents, corticosteroids, or immunosuppressive therapy within 2 years before enrollment, except as specifically permitted by the protocol.
  25. Requirement for chronic systemic immunosuppressive treatment.
  26. Systemic glucocorticoid treatment within 7 days before initiation of systemic study treatment, except physiologic replacement therapy equivalent to prednisone ≤10 mg/day.
  27. Uncontrolled peripheral neuropathy of grade ≥2 or other condition that, in the investigator's judgment, would substantially increase the risk of study treatment.
  28. Psychiatric, cognitive, or other conditions that would prevent adequate informed consent or compliance with study procedures.
  29. Active or Clinically Significant Infection
  30. Active tuberculosis or inadequately controlled tuberculosis treated within 1 year before enrollment.
  31. Human immunodeficiency virus (HIV) infection with clinically significant immunodeficiency or acquired immunodeficiency syndrome (AIDS), as defined by the study protocol.
  32. Active hepatitis B infection with HBV DNA above the protocol-defined acceptable limit.
  33. Active hepatitis C infection with detectable HCV RNA.
  34. Other uncontrolled active infection requiring systemic therapy that, in the investigator's judgment, would interfere with study treatment.
  35. Pulmonary Conditions
  36. Interstitial lung disease, interstitial pneumonia, pneumoconiosis, drug-induced pneumonitis, or other clinically significant diffuse pulmonary disease that may increase the risk of study treatment.
  37. Severe impairment of pulmonary function incompatible with the planned ablation, systemic therapy, or subsequent surgical resection.
  38. Clinically uncontrolled pleural or pericardial effusion. Participants whose effusion is adequately controlled and clinically stable after drainage may be eligible according to investigator assessment and the study protocol.
  39. Other Malignancies
  40. Another malignancy diagnosed within 2 years before enrollment, except malignancies with a negligible risk of metastasis or death that have been adequately treated, such as basal cell or squamous cell carcinoma of the skin or carcinoma in situ treated with curative intent.
  41. Concurrent or Recent Treatments
  42. Participation in another interventional clinical trial or receipt of another investigational drug or investigational device within 4 weeks before the first study intervention.
  43. Receipt of anti-cancer traditional Chinese patent medicines or systemic immunomodulatory agents, including thymosin, interferons, or interleukins, within 2 weeks before initiation of study treatment.
  44. Receipt of a live attenuated vaccine within 30 days before initiation of study treatment. Inactivated vaccines, including inactivated influenza vaccines, are permitted.
  45. Pregnancy, Lactation, and Transplantation
  46. Pregnancy or breastfeeding.
  47. Unwillingness to comply with protocol-specified contraceptive requirements.
  48. Previous organ or bone marrow transplantation, or planned transplantation during the study period.
  49. Other Exclusion Criteria
  50. Known severe hypersensitivity or contraindication to toripalimab, protocol-specified chemotherapy agents, their excipients, or materials used in the ablation procedure.
  51. Any other medical, psychological, social, or logistical condition that, in the investigator's judgment, makes the participant unsuitable for study enrollment or could interfere with treatment safety, protocol compliance, or interpretation of study results.

引自 ClinicalTrials.gov, NCT07855965, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07855965,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07855965